Trial Profile
A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet chemotherapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms CAPITAL
- 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
- 26 Nov 2015 Accrual to date is 37% according to United Kingdom Clinical Research Network record.
- 09 Jul 2015 Accrual to date is 35% according to United Kingdom Clinical Research Network record.